TW202144378A - 親環蛋白抑制劑及其用途 - Google Patents

親環蛋白抑制劑及其用途 Download PDF

Info

Publication number
TW202144378A
TW202144378A TW110110798A TW110110798A TW202144378A TW 202144378 A TW202144378 A TW 202144378A TW 110110798 A TW110110798 A TW 110110798A TW 110110798 A TW110110798 A TW 110110798A TW 202144378 A TW202144378 A TW 202144378A
Authority
TW
Taiwan
Prior art keywords
compound
organ
administered
donor
formula
Prior art date
Application number
TW110110798A
Other languages
English (en)
Chinese (zh)
Inventor
麥靖邦
漢斯 費
馬法書
邁克 溥
Original Assignee
大陸商睿諾醫療科技(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商睿諾醫療科技(上海)有限公司 filed Critical 大陸商睿諾醫療科技(上海)有限公司
Publication of TW202144378A publication Critical patent/TW202144378A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW110110798A 2020-03-26 2021-03-25 親環蛋白抑制劑及其用途 TW202144378A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2020/081296 2020-03-26
CN2020081296 2020-03-26

Publications (1)

Publication Number Publication Date
TW202144378A true TW202144378A (zh) 2021-12-01

Family

ID=77891508

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110110798A TW202144378A (zh) 2020-03-26 2021-03-25 親環蛋白抑制劑及其用途

Country Status (9)

Country Link
US (1) US20230203099A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126903A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023518775A (cg-RX-API-DMAC7.html)
KR (1) KR20220158759A (cg-RX-API-DMAC7.html)
CN (1) CN115315432A (cg-RX-API-DMAC7.html)
AU (1) AU2021244763A1 (cg-RX-API-DMAC7.html)
CA (1) CA3172689A1 (cg-RX-API-DMAC7.html)
TW (1) TW202144378A (cg-RX-API-DMAC7.html)
WO (1) WO2021190603A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN115028679B (zh) * 2022-08-11 2022-11-15 深圳湾实验室 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
CA2518265A1 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
MX2011001152A (es) * 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
AU2011342284C1 (en) * 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
AU2017267560B2 (en) * 2016-05-17 2022-03-24 S&T Global Inc. Novel cyclosporin derivatives and uses thereof
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
CN116870135A (zh) * 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防

Also Published As

Publication number Publication date
AU2021244763A1 (en) 2022-10-06
EP4126903A1 (en) 2023-02-08
CN115315432A (zh) 2022-11-08
CA3172689A1 (en) 2021-09-30
KR20220158759A (ko) 2022-12-01
EP4126903A4 (en) 2024-05-08
US20230203099A1 (en) 2023-06-29
JP2023518775A (ja) 2023-05-08
WO2021190603A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
TWI917366B (zh) 親環蛋白抑制劑及其用途
CN115315432A (zh) 亲环蛋白抑制剂及其用途
JP6862404B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤
JP7839090B2 (ja) ネフロトキシン誘発性腎障害の処置及び予防
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ(cerdulatinib)
NZ569507A (en) Viral hepatitis treatment using nitazoxanide or tizoxanide
US20220160701A1 (en) Methods of treatment and pharmaceutical compositions using bcn057 or bcn512
KR20160110399A (ko) 메갈린 길항제
RU2491934C2 (ru) Лечение фиброзирующих нарушений
EA051978B1 (ru) Ингибиторы циклофилина и их применение